Conclusion
Our retrospective analysis suggested that MC demonstrated clinical benefits for relapsed or refractory pediatric cancers; about half of the progressive tumors presented tumor stabilization and prolonged survival time with higher QOL. The treatment was well tolerated in previously heavily treated patients, and the incidence of AEs decreased compared to conventional chemotherapy. Although large-scale analysis is lacking and many issues need to be resolved, MC can be an important part of cancer treatment.